Measuring exaptation and its impact on innovation, search, and problem solving

Organization Science

Volumn 28, Issue 2, 2017, Pages 320-338

  Andriani, Pierpaolo ^a   Ali, Ayfer ^b   Mastrogiorgio, Mariano ^c  

^a KEDGE BUSINESS SCHOOL   (France)

^b UNIVERSIDAD CARLOS III DE MADRID   (Spain)

^c IE UNIVERSITY   (Spain)

Author keywords

Exaptation; Innovation; Pharmaceutical industry; Problem solving; Radical innovation; Search

Indexed keywords

EID: 85018626981     PISSN: 10477039     EISSN: 15265455     Source Type: Journal    
DOI: 10.1287/orsc.2017.1116     Document Type: Article

References (82)

1. Alexander K (1964) Notes on the Synthesis of Forms (Harvard University Press, Cambridge, MA).
2. Anderson C (2012) Makers: The New Industrial Revolution (Random House, New York).
3. Andriani P, Carignani G (2014) Modular exaptation: A missing link in the synthesis of artificial forms. Res. Policy 43(8):1608-1620.
4. Andriani P, Carignani G (2017) Complex analogy and modular exaptation: Some definitional issues. Mitleton-Kelly E, Paraskevas A, Day C, eds. Handbook of Research Methods in Complexity Science (Edward Elgar, Cheltenham, UK). Forthcoming.
5. Andriani P, Cohen J (2013) From exaptation to radical niche construction in biological and technological complex systems. Complexity 18(5):7-14.
6. Anonymous (2012) The Global Use of Medicines: Outlook Through 2016 (IMS Institute for Healthcare Informatics, Parsippany, NJ).
7. Arthur BA (2009) The Nature of Technology: What Is and How It Evolves (Penguin Books, London).
8. Baldwin C, von Hippel E (2011) Modeling a paradigm shift: From producer innovation to user and open collaborative innovation. Organ. Sci. 22(6):1399-1417.
9. Ban TA (2006) The role of serendipity in drug discovery. Dialogues Clinical Neuroscience 8(3):335-344.
10. Barczak G, Griffin A, Kahn K (2009) Perspective: Trends and drivers of success in NPD practices: Results of the 2003 PDMA best practices study. J. Product Innovation Management 26(1):3-23.
11. Bonaccorsi A (2011) A functional theory of technology and technological change. Antonelli C, ed. Handbook on the Economic Complexity of Technological Change (Edward Elgar, Cheltenham, UK), 286-337.
12. Buderi R (1997) The Invention That Changed theWorld (Simon & Schuster, New York).
13. Cattani G (2005) Preadaptation, firm heterogeneity, and technological performance: A study on the evolution of fiber optics, 1970-1995. Organ. Sci. 16(6):563-580.
14. Cattani G (2006) Technological pre-adaptation, speciation, and emergence of new technologies: How Corning invented and developed fiber optics. Indust. Corporate Change 15(2):285-318.
15. Ching K (2016) Exaptation dynamics and entrepreneurial performance: Evidence from the internet video industry. Indust. Corporate Change 25(1):181-198.
16. Chouduri SP, Van Alstine MW, Parker GG (2016) Platform Revolution (Norton & Company, New York).
17. Clauset A, Shalizi CR, Newman MEJ (2009) Power-law distributions in empirical data. Soc. Indust. Appl. Math. Rev. 51(4):661-703.
18. Cohen MD, March JG, Olsen JP (1972) A garbage can model of organizational choice. Admin. Sci. Quart. 17(1):1-25.
19. Comroe Jr JH (1977) Roast pig and scientific discovery. Part I. Amer. Rev. Respiratory Disease 115(5):853-860.
20. Dawkins R (1986) The Blind Watchmaker (W. W. Norton, New York).
21. DeMonaco HJ, Ali A, Von Hippel E (2006) The major role of clinicians in the discovery of off-label drug therapies. Pharmacotherapy 26(3):323-332.
22. Dew N (2009) Serendipity in entrepreneurship. Organ. Stud. 30(7):735-753.
23. Dew N, Sarasvathy SD (2016) Exaptation and niche construction: Behavioral Insights for an evolutionary theory. Indust. Corporate Change 25(1):167-179.
24. Dew N, Sarasvathy SD, Venkataraman S (2004) The economic implications of exaptation. J. Evolutionary Econom. 14(1):69-84.
25. Dew N, Read S, Sarasvathy SD, Wiltbank R (2008) Outlines of a behavioral theory of the entrepreneurial firm. J. Econom. Behav. Organ. 66(1):37-59.
26. Dudley J, Deshpande T, Butte A (2011) Exploiting drug-disease relationships for computational drug repositioning. Briefings Bioinformatics 12(4):303-311.
27. Felin T, Zenger T (2016) Strategy, problems, and a theory for the firm. Organ. Sci. 27(1):221-231.
28. Felin T, Kauffman S, Koppl R, Longo G (2014) Economic opportunity and evolution: beyond landscapes and bounded rationality. Strategic Entrepreneurship J. 8(4):269-282.
29. Felin T, Kauffman SA, Mastrogiorgio A, Mastrogiorgio M (2016) Factor markets, actors and affordances. Indust. Corporate Change 25(1):133-147.
30. Fleming A (1929) On the antibacterial action of cultures of a Penicillium, with special reference to their use in the isolation of B. influenzae. British J. Experiment. Pathology 10(3):226-236.
31. Garcia R, Calantone R (2002) A critical look at technological innovation typology and innovativeness terminology: A literature review. J. Product Innovation Management 19(2):110-132.
32. Garud R, Nayyar P, Shapira Z (1997) Technological Innovation: Oversights and Foresights (Cambridge University Press, Cambridge, MA).
33. Gavetti G (2012) PERSPECTIVE-Toward a behavioral theory of strategy. Organ. Sci. 23(1):267-285.
34. Gavetti G, Levinthal DA, Rivkin JW (2005) Strategy making in novel and complex worlds: The power of analogy. Strategic Management J. 26(8):691-712.
35. Gelijns A (1998) Capturing the unexpected benefits of medical research. New England J. Medicine 339(10):693-698.
36. Gentner D (1983) Structure-mapping: A theoretical framework for analogy. Cognitive Sci. 7(2):155-170.
37. Gibson J (1986) The Ecological Approach to Visual Perception: Classic Edition (Taylor & Francis, Oxford, UK).
38. Gould SJ (2002) The Structure of Evolutionary Theory (Harvard University Press, Boston).
39. Gould S, Vrba E (1982) Exaptation-A missing term in the science of form. Paleobiology 8(1):4-15.
40. Gundling E (2000) The 3M Way to Innovation: Balancing People and Profit (Kodansha International, Tokyo).
41. Infield GB (1976) Disaster at Bari (New English Library, London).
42. Kauffman S (2000) Investigations (Oxford University Press, Oxford, UK).
43. Knop J, Bonsmann G, Happle R, Ludolph A, Matz DR, Mifsud EJ, Macher E (1983) Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus. British J. Dermatology. 108(4):461-466.
44. KraghH(2008) From disulfiram to antabuse: The invention of a drug. Bull. Hist. Chemistry 33(2):82-88.
45. Latour B (2005) Reassembling the Social: An Introduction to Actor-Network-Theory (Oxford University Press, Oxford, UK).
46. Levinthal D (1998) The slow pace of rapid technological change: Gradualism and punctuation in technological change. Indust. Corporate Change 7(2):217-247.
47. Li JJ (2006) Laughing Gas, Viagra end Libitor: The Human Stories Behind the Drugs We Use (Oxford University Press, Oxford, UK ).
48. Loe M (2004) The Rise of Viagra: How the Little Blue Pill Changed Sex in America (New York University Press, New York).
49. Longo G, Montevil M, Kauffman S (2012) No entailing laws, but enablement in the evolution of the biosphere. Proc. 14th Internat. Conf. Genetic Evolutionary Comput. Conf. Companion, July 7-11, Philadelphia, 1379-1392.
50. Mastrogiorgio M, Gilsing V (2016) Innovation through exaptation and its determinants: The role of technological complexity, analogy making, and patent scope. Res. Policy 45(7):1419-1435.
51. Maxwell RA, Eckardt SB (1990) Chlorpromazine. Maxwell RA, Eckardt SB, eds. Drug Discovery: A Casebook and Analysis (Springer, New York), 111-122.
52. MeyersMA(2007) Happy Accidents: Serendipity in Major Medical Breakthroughs in the Twentieth Century (Arcade, New York).
53. Mintzberg H, Waters J (1985) Of strategies, deliberate and emergent. Strategic Management J. 6(3):257-262.
54. Mukherjee S (2010) The Emperor of All Maladies: A Biography of Cancer (Simon and Schuster, New York).
55. Mukhurjee S (2012) Post-Prozac nation: The science and history of treating depression. New York Times (April 19), http://www.nytimes.com/2012/04/22/magazine/the-science-and-history-of-treating-depression.html.
56. Nebeker F (2009) Dawn of the Electronic Age: Electrical Technologies in the Shaping of the Modern World, 1914 to 1945 (John Wiley, New York).
57. Nerkar A, Roberts PW (2004) Technological and product-market experience and the success of new product introductions in the pharmaceutical industry. Strategic Management J. 25(8-9): 779-799.
58. Osepchuk JM (1984) A history of microwave heating applications. IEEE Trans Microwave Theory Techniques 32(9):1200-1224.
59. Page S (2008) The Difference (Princeton University Press, Princeton, NJ).
60. Radley DC, Finkelstein SN, Stafford RS (2006) Off-label prescribing among office-based physicians. Arch. Internal Medicine 166(9):1021-1026.
61. Read S, Sarasvathy S, Dew N, Wiltbank R, Ohlsson A (2010) Effectual Entrepreneurship (Taylor & Francis, Oxford, UK).
62. Rehman W, Arfons L, Lazarus H (2011) The rise, fall and subsequent triumph of thalidomide. Therapeutic Advances Hematology 2(5):291-308.
63. Roin BN (2014) Solving the problem of new uses. Working paper, Massachusetts Institute of Technology, Cambridge, MA.
64. Schirmer R, Adlera M, Pickhardt M, Mandelkow E (2011) 'Lest we forget you-Methylene blue:::.' Neurobiology Aging 32(2325): 2325.e7-2325.e16.
65. Schön DA (1983) The Reflective Practitioner? How Professionals Think in Action (Basic Books, New York).
66. Sheskin J (1965) Thalidomide in the treatment of lepra reactions. Clinical Pharmacology Therapeutics 6(3):303-306.
67. Stephens TD, Brynner R (2009) Dark Remedy: The Impact of Thalidomide and Its Revival as a Vital Medicine (Basic Books, New York).
68. TalebN(2012) Anti-Fragile: How to Live in aWorldWe Don't Understand (Allen Lane, London).
69. Terwiesch C, Ulrich KT (2009) Innovation Tournaments (Harvard Business Press, Cambridge, MA).
70. Tillman K, Burton B, Jacques LB, Phurrough SE (2009) Compendia and anticancer therapy under Medicare. Ann. Internal Medicine 150(5):348-350.
71. Tone A (2008) The Age of Anxiety: A History of America's Turbulent Affair with Tranquilizers (Basic Books, New York).
72. Topaz M, Shafran-Topaz L, Bowles KH (2013) ICD-9 to ICD-10: evolution, revolution, and current debates in the United States. Perspect. Health Inform. Management 10(Spring):1-8.
73. Vallery-Radot R (1902) The Life of Pasteur (McClure, Phillips and Co., New York).
74. Van de Ven AH, Polley DE, Garud R, Venkataraman S (1999) The Innovation Journey (Oxford University Press, Oxford, UK).
75. Ventola CL (2009) Off-label drug information: Regulation, distribution, evaluation, and related controversies. P T 34(8):428-440.
76. von Hippel E (2005) Democratizing Innovation (MIT Press, Cambridge, MA).
77. von Hippel E, von Krogh G (2016) Identifying viable 'need-solution pairs': Problem solving without problem formulation. Organ. Sci. 27(1):207-221.
78. von Hippel EA, DeMonaco HJ, de Jong JPJ (2016) Market failure in the diffusion of user innovations: The case of 'off-label' innovations by medical clinicians.Working paper, Massachusetts Institute of Technology, Cambridge, MA.
79. Wagner A (2011) The Origins of Evolutionary Innovations (Oxford University Press, Oxford, UK).
80. Wiener N (1993) Invention: The Care and Feeding of Ideas (MIT Press, Cambridge, MA).
81. Winter S (2012) Purpose and progress in the theory of strategy: Comments on Gavetti. Organ. Sci. 23(1):288-297.
82. Woolf S (2008) The meaning of translational research and why it matters. Jama 299(2):211-213.